Equities

Organon Pharma Indonesia Tbk PT

SCPI:JKT

Organon Pharma Indonesia Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)29,000.00
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 10 minutes, as of Jan 07 2013.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PT Organon Pharma Indonesia Tbk is an Indonesia-based pharmaceutical company. The Company is engaged in the processing, packaging and development of pharmaceutical products for human and animal consumption, toiletries, cosmetics, household and related products. The Company is also engaged in importing of raw materials, finished goods and providing business and management consultancy services. The Company’s segments include Pharmaceutical Manufacturing and commercial. For women's health, the Company develops product specifically for women, including contraception, fertility, pregnancy management, perinatal diseases and other diseases.

  • Revenue in IDR (TTM)2.86tn
  • Net income in IDR161.86bn
  • Incorporated1972
  • Employees212.00
  • Location
    Organon Pharma Indonesia Tbk PTGedung Wisma BNI 46Lantai 27 Jln Jendral Sudirman Kav.1JAKARTA SELATAN 12920IndonesiaIDN
  • Phone+62 2 157897000
  • Fax+62 2 131107009
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Firebrick Pharma Ltd0.00-48.59bn123.95bn----7.28-----0.0266-0.02660.000.00890.00-------120.70---136.04----------4.37--0.00---79.85---79.18------
Nyrada Inc32.76bn-52.95bn124.02bn----2.21--3.79-0.0319-0.03190.01980.02940.3983-------64.37-64.90-71.93-84.66-----161.62-380.62---15,086.390.00--42.54229.09-96.52------
Tissue Repair Ltd4.87bn-34.85bn130.57bn----0.7724--26.84-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
Bioxyne Ltd92.04bn-150.68bn130.59bn16.00--3.94--1.42-0.0074-0.00740.00440.00151.836.1210.50---302.23-22.07-418.10-28.5038.3045.13-165.04-39.691.50--0.00--1,013.0520.97-292.69---19.86--
Adalta Ltd37.88bn-53.64bn136.08bn----5.21--3.59-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Organon Pharma Indonesia Tbk PT2.86tn161.86bn145.13bn212.00----0.72150.050844,960.0244,960.02794,244.70246,656.201.886.008.1714,368,320,000.0010.6311.4116.0115.869.5912.575.666.781.1876.190.007--17.454.497.398.11-14.93--
Extrawell Pharmaceutical Holdings Ltd140.08bn-314.94bn146.36bn169.00--0.0689--1.04-0.0776-0.07760.02090.43540.05387.479.89379,132.60-12.004.62-12.504.8847.3651.97-223.0773.993.38-0.05140.09680.00-1.82-3.28-1.0133.99121.54--
Mono Pharmacare Ltd-19.08tn-19.08tn146.98bn--------------------------------------------------58.12--251.10------
Patrys Ltd18.03bn-54.50bn153.16bn15.00--2.87--8.50-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Data as of Jan 07 2013. Currency figures normalised to Organon Pharma Indonesia Tbk PT's reporting currency: Indonesian Rupiah IDR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.